Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone

Inclusion Criteria: \- 1. Children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone who have received treatment with somotarogon or have been determined to start treatment with somatrogon according to the approved indications of the medicinal product; 2\. Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study. Exclusion Criteria: 1. Patients concurrently participating in other studies involving therapeutic interventions and/or investigational products; 2. Patients who have contraindications to somatrogon as specified in the approved LPD. 3. Patients with hypersensitivity or case history to somatrogon or to any of the excipients in the product